Roflumilast in chronic obstructive pulmonary disease: evidence from large trials

Bibliography

• Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004;59:574-80
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long acting beta2-agonists and corticosteroids in stable COPD. Chest 2004;126:220-37
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-29
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X, Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-19
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M. New anti-inflammatory approaches in COPD. Drug Discov Today Ther Strateg 2004;1:335-43
   Google Scholar
• Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237-43
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006;147 (Suppl 1):S252-7
   PubMedGoogle Scholar
• Horowski R, Sastre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 1985;38:23-9
   Web of Science ®Google Scholar
• Torphy TJ, Barnette MS, Underwood DC, Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5
   PubMed Web of Science ®Google Scholar
• Rennard S, Knobil K, Rabe KF, The efficacy and safety of cilomilast in COPD. Drugs 2008;68 (Suppl 2):3-57
   Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101
   PubMed Web of Science ®Google Scholar
• Bundschuh DS, Eltze M, Barsig J, In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53
   PubMed Web of Science ®Google Scholar
• Mata M, Sarria B, Buenestado A, Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-52
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
   PubMed Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Verhoosel RM, The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007;62:1081-7
   PubMed Web of Science ®Google Scholar
• Rabe KF, Bateman ED, O'Donnell D, Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-72
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
   PubMed Web of Science ®Google Scholar
• Committee for proprietary medicinal products (CPMP). Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). Available from: http://www.emea.europa.eu/pdfs/ human/ewp/056298en.pdf [Last accessed 18 October 2009]
   Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-13
   PubMedGoogle Scholar
• Yang IA, Fong KM, Sim EH, Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;2:CD002991
   PubMed Web of Science ®Google Scholar
• Puhan MA, Bachmann LM, Kleijnen J, Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Hodder R, Kesten S, Menjoge S, Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulm Dis 2007;2:157-67
   PubMedGoogle Scholar
• Celli B. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Chest 2006;129:5-6
   PubMed Web of Science ®Google Scholar
• van Grunsven PM, van Schayck CP, Derenne JP, Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14
   PubMed Web of Science ®Google Scholar
• Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-42
   PubMedGoogle Scholar
• Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-15
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006;109:238-45
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cieslinski LB, Newton R, Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)- 4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004;66:1679-89
   PubMed Web of Science ®Google Scholar
• Underwood DC, Kotzer CJ, Bochnowicz S, Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994;270:250-9
   PubMedGoogle Scholar
• Boswell-Smith V, Spina D, Oxford AW, The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy- 2(2,4,6-trimethylphenylimino)- 3-(n-carbamoyl-2-aminoethyl) -3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)- 9,10-dimethoxy-4H-pyrimido[6,1-a]i soquinolin-4-one]. J Pharmacol Exp Ther 2006;318:840-8
   PubMed Web of Science ®Google Scholar